Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: A systematic review

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 10, 2009, Pages 1210-1218

  Varadi, R G ^a   Marras, Theodore K ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Characteristics; Drug; Mycobacterium xenopi; Systematic review; Treatment

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DRUG SPECIFICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LUNG INFECTION; MIDDLE AGED; MORTALITY; MYCOBACTERIOSIS; MYCOBACTERIUM XENOPEI; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM XENOPI; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 70350102842     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Schwabacher H. A strain of Mycobacterium isolated from skin lesions of a cold-blooded animal, Xenopus laevis, and its relation to atypical acid-fast bacilli occurring in man. J Hyg (Lond) 1959; 57: 57-67.
2. Griffith D E, Aksamit T, Brown-Elliott B A, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of non-tuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416. (Pubitemid 46271561)
3. Astagneau P, Desplaces N, Vincent V, et al. Mycobacterium xenopi spinal infections after discovertebral surgery: investigation and screening of a large outbreak. Lancet 2001; 358: 747-751. (Pubitemid 32823408)
4. Huang D B, Gupta A, Gupta G. Psoas abscess due to Mycobacterium xenopi infection. Am J Med 2003; 114: 247-249. (Pubitemid 36294018)
5. Marks J, Cook J, Pringle J A. Bone abscess due to Mycobacterium xenopi. Tubercle 1975; 56: 157-159.
6. Salliot C, Desplaces N, Boisrenoult P, et al. Arthritis due to Mycobacterium xenopi: a retrospective study of 7 cases in France. Clin Infect Dis 2006; 43: 987-993. (Pubitemid 44631097)
7. Yates M D, Grange J M, Collins C H. The nature of mycobacterial disease in south east England, 1977-1984. J Epidemiol Community Health 1986; 40: 295-300.
8. Marras T K, Daley C L. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med 2002; 23: 553-567.
9. Marras T K, Chedore P, Ying A M, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997-2003. Thorax 2007; 62: 661-666.
10. Martin-Casabona N, Bahrmand A R, et al. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis 2004; 8: 1186-1193. (Pubitemid 39371831)
11. Smith M J, Citron K M. Clinical review of pulmonary disease caused by Mycobacterium xenopi. Thorax 1983; 38: 373-377.
12. Banks J, Hunter A M, Campbell I A, Jenkins P A, Smith A P. Pulmonary infection with Mycobacterium xenopi: review of treatment and response. Thorax 1984; 39: 376-382. (Pubitemid 14140409)
13. Jenkins P A, Campbell I A, Research Committee of The British Thoracic Society. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five-year follow-up of patients receiving standardised treatment. Respir Med 2003; 97: 439-444.
14. Contreras M A, Cheung O T, Sanders D E, Goldstein R S. Pulmonary infection with non-tuberculous mycobacteria. Am Rev Respir Dis 1988; 137: 149-152.
15. Thomas P, Liu F, Weiser W. Characteristics of Mycobacterium xenopi disease. Bull Int Union Tuberc Lung Dis 1988; 63 (3): 12-13.
16. Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M. avium intracellulare, M. malmoense and M. xenopi in HIV-negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001; 56: 167-172.
17. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 2000; 55: 210-218.
18. Al Jarad N, Demertzis P, Jones D J, et al. Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis. Thorax 1996; 51: 137-139. (Pubitemid 126424055)
19. Andrejak C, Lescure F X, Douadi Y, et al. Non-tuberculous mycobacteria pulmonary infection: management and follow-up of 31 infected patients. J Infect 2007; 55: 34-40. (Pubitemid 46888075)
20. Baugnee P E, Pouthier F, Delaunois L. Pulmonary mycobacteriosis due to Mycobacterium xenopi: in-vitro sensitivity to classical anti-tubercular agents and clinical development. Acta Clin Belg 1996; 51: 19-27.
21. Beck A, Keeping J A, Zorab P A. Anonymous mycobacteria in man and wife. Tubercle 1963; 44: 378-380.
22. Beck A, Stanford J L. Mycobacterium xenopei: a study of sixteen strains. Tubercle 1968; 49: 26-34.
23. Bellamy J, Leroy-Terquem E, Duhamel J P, et al. Mycobacterium xenopi infection in emphysematous bulla. Apropos of 4 cases operated on. Rev Mal Respir 1987; 4: 261-264.
24. Bennett S N, Peterson D E, Johnson D R, Hall W N, Robinson-Dunn B, Dietrich S. Bronchoscopy-associated Mycobacterium xenopi pseudoinfections. Am J Respir Crit Care Med 1994; 150: 245-250.
25. Benoit J P, Monchamps G, Deniau A, Oberlin F, Paley P Y, Zaegel N. Une petite epidemie de mycobactéries atypiques à 'xenopi' survenue à l'annexe du Centre Hospitalier de Chartres. Rev Fr Mal Respir 1982; 10: 453. [French]
26. Bogaerts Y, Elinck W, van Renterghem D, Pauwels R, van der Straeten M. Pulmonary disease due to Mycobacterium xenopi. Report of two cases. Eur J Respir Dis 1982; 63: 298-304. (Pubitemid 12086262)
27. Brocard H, Gallouedec P, Accard J L, Broquie G, Boucker M. Les mycobacterioses pulmonaires à Mycobacterium xenopi. Rev Fr Mal Respir 1974; 2: 180-193. [French]
28. Costrini A M, Mahler D A, Gross W M, Hawkins J E, Yesner R, D'Esopo N D. Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis 1981; 123: 104-109.
29. Dailloux M, Abalain M L, Laurain C, et al. Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. 2006; 28: 1211-1215.
30. Dautzenberg B, Papillon F, Lepitre M, Truffot-Pernod C H, Chauvin J P. Mycobacterium xenopi infections treated with clarithromycin containing regimens [Abstract no. 1125]. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC, USA: Am Soc for Microbiology, 1993: p 417.
31. Desbordes-Lize J, Liaudct J, Savigny G, Lelieur G M, Fouye G. Le Mycobacterium xenopi en clinique humaine. A propos d'une invasion hospitaliere et de 300 dossiers cliniques. Med Int 1970; 5: 353-364. [French]
32. Dixmier A, Meynard J L, Lalande V, Lebeau B, Chouaid C. [Pulmonary infections with Mycobacterium xenopi in patients without HIV infection]. Rev Mal Respir 2007; 24: 299-304. [French]
33. Donnabella V, Salazar-Schicchi J, Bonk S, Hanna B, Rom W N. Increasing incidence of Mycobacterium xenopi at Bellevue hospital: an emerging pathogen or a product of improved laboratory methods? Chest 2000; 118: 1365-1370.
34. Dwelshauwers F, Hennebert A, Korsak T, Millet M. Human infections from 'Mycobacterium xenopei'. Acta Tuberc Pneumol Belg 1966; 57: 353-372.
35. Engbaek H C, Vergmann B, Baess I, Will D W. M. xenopei: a bacteriological study of M. xenopei including case reports of Danish patients. Acta Pathol Microbiol Scand 1967; 69: 577-594.
36. Froidure M, Massin F, Duez J M, Baudouin N, Camus P, Jeannin L. Lung disease due to Mycobacterium xenopi excluding AIDS. Apropos of 8 cases. Rev Mal Respir 2000; 17: 481-487.
37. Hollings N P, Wells A U, Wilson R, Hansell D M. Comparative appearances of non-tuberculous mycobacteria species: a CT study. Eur Radiol 2002; 12: 2211-2217. (Pubitemid 36940315)
38. Horak Z, Polakova H, Kralova M. Water-borne Mycobacterium xenopi - a possible cause of pulmonary mycobacteriosis in man. J Hyg Epidemiol Microbiol Immunol 1986; 30: 405-409.
39. Jiva T M, Jacoby H M, Weymouth L A, Kaminski D A, Portmore A C. Mycobacterium xenopi: innocent bystander or emerging pathogen? Clin Infect Dis 1997; 24: 226-232.
40. Jenkins P A, Campbell I A, Banks J, Gelder C M, Prescott R J, Smith A P. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in the treatment of opportunist mycobacterial pulmonary diseases and an assessment of the value of immunotherapy with M. vaccae: a pragmatic, randomised trial by the British Thoracic Society. Thorax 2008; 63: 627-634.
41. Johnston I D. Mycobacterium xenopi infection and aspergilloma. Tubercle 1988; 69: 139-143.
42. Jouveshomme S, Dautzenberg B, Bakdach H, Derenne J P. Preliminary results of collapse therapy with plombage for pulmonary disease caused by multidrug-resistant mycobacteria. Am J Respir Crit Care Med 1998; 157: 1609-1615. (Pubitemid 28242099)
43. Kim T C, Arora N S, Aldrich T K, Rochester D F. Atypical mycobacterial infections: a clinical study of 92 patients. South Med J 1981; 74: 1304-1308.
44. Korsak T, Leblanc G, Millet M. Observations relatives à Mycobacterium xenopei en Belgique. Acta Tuberc Pneumol Belg 1969; 60: 141-158. [French]
45. Lang-Lazdunski L, Offredo C, Le Pimpec-Barthes F, Danel C, Dujon A, Riquet M. Pulmonary resection for Mycobacterium xenopi pulmonary infection. Ann Thorac Surg 2001; 72: 1877-1882. (Pubitemid 34001432)
46. Lavy A, Rusu R, Mates A. Mycobacterium xenopi, a potential human pathogen. Isr J Med Sci 1992; 28: 772-775.
47. Marks J, Schwabacher H. Infection due to Mycobacterium xenopei. Br Med J 1965; 1: 32-33.
48. Parrot R, Braun J M, Gaillard J P, Sors C H, Grosset J. Les Mycobacterioses pulmonaires à M. xenopi. A propos de 50 cas. Elements de diagnostic. Rev Fr Mal Respir 1979; 7: 501-503. [French]
49. Sors C, Gaillard J P, Braun J M, Grosset J. Les mycobactérioses pulmonaires à M. xenopi. A propos de 50 cas. Modalités évolutives et problèmes thérapeutiques. Rev Fr Mal Resp 1979; 7: 504-506. [French]
50. Parrot R G, Grosset J H. Post-surgical outcome of 57 patients with Mycobacterium xenopi pulmonary infection. Tubercle 1988; 69: 47-55.
51. Simor A E, Salit I E, Vellend H. The role of Mycobacterium xenopi in human disease. Am Rev Respir Dis 1984; 129: 435-438. (Pubitemid 14197263)
52. Sniadack D H, Ostroff S M, Karlix M A, et al. A nosocomial pseudo-outbreak of Mycobacterium xenopi due to a contaminated potable water supply: lessons in prevention. Infect Control Hosp Epidemiol 1993; 14: 636-641.
53. Szabo I, Kiss K K, Varnai I. Epidemic pulmonary infection associated with Mycobacterium xenopi indigenous in sewage-sludge. Acta Microbiol Acad Sci Hung 1982; 29: 263-266.
54. Tellis C J, Beechler C R, Ohashi D K, Fuller S A. Pulmonary disease caused by Mycobacterium xenopi: two case reports. Am Rev Respir Dis 1977; 116: 779-783. (Pubitemid 8206011)
55. Terashima T, Sakamaki F, Hasegawa N, Kanazawa M, Kawashiro T. Pulmonary infection due to Mycobacterium xenopi. Intern Med 1994; 33: 536-539.
56. Teyssier L, Rocher R, Ruffino J, Lesobre R. Pneumopathy due to Mycobacterium xenopei. Ann Med Interne (Paris) 1970; 121: 505-517.
57. Thaunat O, Morelon E, Stern M, et al. Mycobacterium xenopi pulmonary infection in two renal transplant recipients under sirolimus therapy. Transpl Infect Dis 2004; 6: 179-182. (Pubitemid 40516686)
58. Thibier R, Vivien J N, Lepeuple A, Boivert H, Moreau J. Infections humaines à Mycobacterium xenopi. Gazette Med Fr 1971; 78: 2087-2100. [French]
59. Tortoli E, Simonetti M T, Labardi C, et al. Mycobacterium xenopi isolation from clinical specimens in the Florence area: review of 46 cases. Eur J Epidemiol 1991; 7: 677-681.
60. Vayssairat M, Moulias R, Rameix P, Grosset J, Chomette G, Loeper J. Two new cases of pulmonary mycobacteriosis due to Mycobacterium xenopi. Ann Med Interne (Paris) 1973; 124: 309-312.
61. Wittram C, Weisbrod G L. Mycobacterium xenopi pulmonary infection: evaluation with CT. J Comput Assist Tomogr 1998; 22: 225-228. (Pubitemid 28155194)
62. Heifets L B. Dilemmas and realities in drug susceptibility testing of M. avium-M. intracellular and other slowly growing non-tuberculous mycobacteria. In: Heifets L B, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL, USA: CRC Press, 1991: pp 123-147.
63. Klemens S P, Cynamon M H. Activities of azithromycin and clarithromycin against non-tuberculous mycobacteria in beige mice. Antimicrob Agents Chemother 1994; 38: 1455-1459. (Pubitemid 24203551)
64. Lounis N, Truffot-Pernot C, Bentoucha A, Robert J, Ji B, Grosset J. Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. Antimicrob Agents Chemother 2001; 45: 3229-3230.
65. Banks J, Jenkins P A. Combined versus single anti-tuberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria. Thorax 1987; 42: 838-842. (Pubitemid 17160880)